Liver, heart, kidney and brain drug-induced toxicities currently account for more than 70% of drug attrition and drug withdrawal. Porsolt has developed a range of organ-specific cell-based assays to better predict the toxicity potential of drug candidates.
Based on highly predictive cellular models, i.e. primary cell cultures, we perform functional toxicity assays and offers to investigate the signaling pathways involved in detoxification and oxidative stress induced by the drug compound.
IN VIVO | ||
Acute toxicity | Rat - Mouse - Dog - Mini-pig | TOX 11 |
Preliminary chronic toxicity |
Rat - Mouse | TOX 12 |
IN VITRO | ||
Cholestasis/Bile canaliculi network | Primary hepatocytes (H,R,M) sandwich configuration | PF 3.16 |
Lipid, intracellular accumulation: triglycerides | Primary hepatocytes (H,R,M) HepG2 | PF 3.30 |
NAD(P)H/FAD | Primary hepatocytes (H,R,M) HepG2 | PF 3.31 |
Mitochondrial membrane potential | Primary hepatocytes (H,R,M) HepG2 | PF 3.3 |
Cytolysis | Primary hepatocytes (H,R,M) HepG2 | PF 3.4 |
MRP2 expression measurement | Primary hepatocytes - sandwich configuration- hepatic tissue |
PF 3.5 |
IN VITRO | ||
Lysosomal activity |
Primary human renal proximal tubule epithelial cells Human renal proximal tubule epithelial cell line (HK-2) |
PF 3.7 |
Mitochondrial membrane potential | PF 3.3 | |
Cytolis | PF 3.4 |
IN VITRO | ||
Neurite outgrowth |
Primary neurons (R,M) iPSC derived neurons, |
PF 3.6 |
Cytolysis | PF 3.4 | |
Caspase 3/7 activation | PF 3.2 |
IN VITRO | ||
Histone H2AX phosphorylation | Multiple cellular models | PF 5.1 |
IN VIVO | ||
Mammalian erythrocyte micronucleus assay |
Rat | TOX 17 |
IN VITRO | ||
Drug Induced Vascular Injury (Endothelial Cell Activation markers) |
HUVECs |
PF 11.1 |
COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA): | ||
Proarrhythmic risk assessment (MEA & Calcium transient assay) |
human-induced pluripotentstem cell-derived cardiomyocytes (hiPSC-CMs) | CV 5.14 |
Electrophysiology measurement (conventional manual patch-clamp) | Cardiac ion channels | CV 5.6 to CV 5.9 |